Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical Cancer
-
摘要:目的
探讨CD44v6和EGFR的表达对Ⅱ~Ⅲ期宫颈癌新辅助化疗（NACT）疗效的预测价值。
方法选择经病理确诊的Ⅱ~Ⅲ期宫颈癌患者53例，所有患者均行2周期紫杉醇+铂类的NACT，收集NACT前的宫颈肿瘤病理组织标本，免疫组织化学SP法检测CD44v6和EGFR的表达，并分析其与Ⅱ~Ⅲ期宫颈癌NACT疗效的相关性。
结果53例患者中NACT敏感组（CR+PR）38例，NACT不敏感组（SD+PD）15例，不敏感组CD44v6的表达显著高于敏感组（P < 0.05）；CD44v6的表达在疗效为CR、PR、SD的患者中具有明显差异（P < 0.05）。CD44v6对Ⅱ~Ⅲ期宫颈癌NACT疗效的AUC为0.74，P < 0.05；与CD44v6低表达组患者相比，高表达组NACT疗效更差（P < 0.05）。Pearson检验发现CD44v6和EGFR表达具有相关性（R=0.34, P < 0.05）。
结论CD44v6和EGFR表达呈正相关。CD44v6高表达可能会降低Ⅱ~Ⅲ期宫颈癌NACT的疗效，CD44v6表达对宫颈癌紫杉醇+铂类NACT疗效有一定预测价值和临床意义。
Abstract:ObjectiveTo explore the predictive value of the expression of CD44v6 and EGFR on the efficacy of neoadjuvant chemotherapy (NACT) in stageⅡ-Ⅲ cervical cancer.
MethodsA total of 53 patients with stageⅡ-Ⅲ cervical cancer diagnosed by pathology were selected. All patients received two cycles of paclitaxel+platinum NACT. The pathological tissue samples of cervical tumors before NACT treatment were collected. The expression of CD44v6 and EGFR were detected by the immunohistochemical SP method, and we analyzed their predictive value of NACT in stageⅡ-Ⅲ cervical cancer.
ResultsAmong the 53 patients, 38 were in the NACT effective group (CR+PR), and 15 were in the NACT ineffective group (SD+PD). The expression of CD44v6 in the ineffective group was significantly higher than that in the effective group (P < 0.05). The expression of CD44v6 was significantly different in patients with CR, PR, and SD (P < 0.05). The AUC of CD44v6 to NACT effect on stage Ⅱ-Ⅲ cervical cancer was 0.74 (P < 0.05). The patients in the high expression group of CD44v6 had worse efficacy in NACT than those in the low expression group of CD44v6 (P < 0.05). Pearson test showed that CD44v6 and EGFR expression were correlated (R=0.34, P < 0.05).
ConclusionHigh expression of CD44v6 may reduce the efficacy of NACT in stageⅡ-Ⅲ cervical cancer, suggesting that the expression of CD44v6 has a certain predictive value and clinical significance in the efficacy of paclitaxel+platinum NACT on cervical cancer. Moreover, CD44v6 is positively correlated with EGFR expression.
-
Key words:
- Cervical cancer /
- Neoadjuvant chemotherapy /
- CD44v6 /
- EGFR
-
Competing interests: The authors declare that they have no competing interests.作者贡献毛万丽：数据收集、论文写作、统计分析冉立、常建英：方案设计指导、数据收集李杰慧：课题方案设计、论文写作指导李凤虎：论文写作指导、数据收集穆珺玉、梅烦、胡丽丽、杜燕君、田雪、秦瑶、殷水水：数据收集
-
![]()
图 1 免疫组织化学检测CD44v6和EGFR的表达
Figure 1 Expression of CD44v6 and EGFR detected by immunohistochemical method
![]()
图 2 CD44v6、EGFR对NACT疗效预测的ROC曲线
Figure 2 ROC curve of CD44v6 and EGFR for predicting NACT efficacy
![]()
图 3 CD44v6与EGFR表达的相关性分析
Figure 3 Correlation analysis between CD44v6 and EGFR expression
表 1 53例宫颈癌患者基线资料表(n(%))
Table 1 Baseline characteristics of 53 cervical cancer patients (n(%))
下载: 导出CSV
表 2 CD44v6、EGFR的表达与53例宫颈癌患者临床特征的关系
Table 2 Correlation of CD44v6 and EGFR expression with clinical features of 53 cervical cancer patients
下载: 导出CSV
表 3 CD44v6、EGFR的表达与NACT敏感度的关系
Table 3 Correlation of CD44v6 and EGFR expression with sensitivity of NACT
下载: 导出CSV
表 4 CD44v6、EGFR对NACT疗效的预测价值
Table 4 Predictive value of CD44v6 and EGFR $[0[]0]n the efficacy of NACT
下载: 导出CSV
表 5 CD44v6、EGFR的表达与NACT疗效的关系
Table 5 Correlation of CD44v6 and EGFR expression with efficacy of NACT
下载: 导出CSV
-
[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2] Kong SY, Huang K, Zeng C, et al. The association between short-term response and long-term survival for cervical cancer patients undergoing neoadjuvant chemotherapy: a system review and meta-analysis[J]. Sci Rep, 2018, 8(1): 1545. doi: 10.1038/s41598-018-19948-0
[3] Zhu H, Luo H, Zhang W, et al. Molecular mechanisms of cisplatin resistance in cervical cancer[J]. Drug Des Devel Ther, 2016, 10: 1885-1895.
[4] 邹婷婷, 郑春莹, 张志邦, 等. 187例ⅠB2和ⅡA2期宫颈癌新辅助化疗疗效及预后的影响因素[J]. 中南大学学报(医学版), 2020, 45(3): 297-304. Zou TT, Zheng CY, Zhang ZB, et al. Neoadjuvant chemotherapy efficacy and prognostic factors in 187 cervical cancer patients with ⅠB2 and ⅡA2 stage[J]. Zhong Nan Da Xue Xue Bao (Yi Xue Ban), 2020, 45(3): 297-304.
[5] Hu B, Luo W, Hu RT, et al. Meta-Analysis of Prognostic and Clinical Significance of CD44v6 in Esophageal Cancer[J]. Medicine (Baltimore), 2015, 94(31): e1238. doi: 10.1097/MD.0000000000001238
[6] Costa S, Terzano P, Bovicelli A, et al. CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma[J]. Gynecol Oncol, 2001, 80(1): 67-73. doi: 10.1006/gyno.2000.6016
[7] Hugo de Almeida V, Guimarães IDS, Almendra LR, et al. Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer[J]. Oncotarget, 2018, 9(55): 30594-30609. doi: 10.18632/oncotarget.25748
[8] 刘萍. 中国大陆13年宫颈癌临床流行病学大数据评价[J]. 中国实用妇科与产科杂志, 2018, 34(1): 41-45. doi: 10.19538/j.fk2018010111 Liu P. Evaluation of big data on clinical epidemiology of cervical cancer in Chinese Mainland in the past 13 years[J]. Zhongguo Shi Yong Fu Ke Yu Chan Ke Za Zhi, 2018, 34(1): 41-45. doi: 10.19538/j.fk2018010111
[9] Zhu Y, Yang J, Zhang X, et al. Acquired treatment response from neoadjuvant chemotherapy predicts a favorable prognosis for local advanced cervical cancer: A meta-analysis[J]. Medicine (Baltimore), 2018, 97(17): e0530. doi: 10.1097/MD.0000000000010530
[10] Prochazka L, Tesarik R, Turanek J. Regulation of alternative splicing of CD44 in cancer[J]. Cell Signal, 2014, 26(10): 2234-2239. doi: 10.1016/j.cellsig.2014.07.011
[11] Yan Y, Zuo X, Wei D. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target[J]. Stem Cells Transl Med, 2015, 4(9): 1033-1043. doi: 10.5966/sctm.2015-0048
[12] Todaro M, Gaggianesi M, Catalano V, et al. CD44V6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis[J]. Cell Stem Cell, 2014, 14(3): 342-356. doi: 10.1016/j.stem.2014.01.009
[13] Zöller M. CD44, Hyaluronan, the Hematopoietic Stem Cell, and Leukemia-Initiating Cells[J]. Front Immunol, 2015, 6: 235.
[14] Ma L, Dong L, Chang P. CD44v6 engages in colorectal cancer progression[J]. Cell Death Dis, 2019, 10(1): 30. doi: 10.1038/s41419-018-1265-7
[15] Senbanjo LT, Chellaiah MA. CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells[J]. Front Cell Dev Biol, 2017, 5: 18.
[16] Hara T, Makino T, Yamasaki M, et al. Effect of c-Met and CD44v6 Expression in Resistance to Chemotherapy in Esophageal Squamous Cell Carcinoma[J]. Ann Surg Oncol, 2019, 26(3): 899-906. doi: 10.1245/s10434-018-07126-5
[17] Fang M, Wu J, Lai X, et al. CD44 and CD44v6 are Correlated with Gastric Cancer Progression and Poor Patient Prognosis: Evidence from 42 Studies[J]. Cell Physiol Biochem, 2016, 40(3-4): 567-578. doi: 10.1159/000452570
[18] Ayhan A, Baykal C, Al A, et al. Altered CD44 variant 6 expression in FIGO stageⅠB cervical carcinoma[J]. Gynecol Oncol, 2001, 83(3): 569-574. doi: 10.1006/gyno.2001.6406
[19] Pereira C, Ferreira D, Mendes N, et al. Expression of CD44v6-Containing Isoforms Influences Cisplatin Response in Gastric Cancer Cells[J]. Cancers (Basel), 2020, 12(4): 858. doi: 10.3390/cancers12040858
[20] Safa AR. Resistance to Cell Death and Its Modulation in Cancer Stem Cells[J]. Crit Rev Oncog, 2016, 21(3-4): 203-219. doi: 10.1615/CritRevOncog.2016016976
[21] 郑晓霞, 孙树兰, 苏晋, 等. 表皮生长因子受体和环氧合酶-2在宫颈癌中的表达及临床诊断意义[J]. 国际免疫学杂志, 2017, 40(2): 161-164. Zheng XX, Sun SL, Su J, et al. The expression and clinical diagnostic significance of epidermal growth factor receptor and cycloxy genase-2 in cervical cancer[J]. Guo Ji Mian Yi Xue Za Zhi, 2017, 40(2): 161-164.
[22] 陈永发, 杨文, 潘兴喜, 等. EGFR、VEGF、Ki-67、PTEN在宫颈癌组织中的表达及其临床意义[J]. 癌症进展, 2019, 17(12): 1465-1468, 1472. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ201912027.htm Chen YF, Yang W, Pan XX, et al. Expression of EGFR, VEGF, Ki-67 and PTEN in cervical cancer and their clinical significance[J]. Ai Zheng Jin Zhan, 2019, 17(12): 1465-1468, 1472. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ201912027.htm
[23] Ruibal Á, Aguiar P, Del Río MC, et al. Cell membrane CD44V6 levels in squamous cell carcinoma of the lung: association with high cellular proliferation and high concentrations of EGFR and CD44v5[J]. Int J Mol Sci, 2015, 16(3): 4372-4378. doi: 10.3390/ijms16034372
[24] 彭俊, 黄勇. 90例年轻宫颈癌患者临床特征及术后复发和预后相关因素分析[J]. 实用妇产科杂志, 2016, 32(1): 42-45. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWVJ201814080.htm Peng J, Huang Y. The Clinical Characteristics, Postoperative Reoccurrence and Prognosis Related Facors of 90 Young Women with Cervical Cancer[J]. Shi Yong Fu Chan Ke Za Zhi, 2016, 32(1): 42-45. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWVJ201814080.htm
[25] 李玉林. 病理学[M]. 第8版. 北京: 人民卫生出版社, 2013. Li YL. Pathology[M]. 8th ed. Beijing: People's Medical Publishing House, 2013.
-
期刊类型引用(1)
1. 梁国刚，周云鹏，王龙辉，陈玉，冯立宗，王顺正，孙国志. 腹腔镜袢式回肠造口还纳术的临床效果分析:一项单中心回顾性研究. 结直肠肛门外科. 2024(05): 557-561 . 
百度学术
其他类型引用(0)
计量
- 文章访问数: 1673
- HTML全文浏览量: 565
- PDF下载量: 275
- 被引次数: 1
